Biohaven falls after depression drug fails mid-stage trial
26/12/2025 10:17
** Shares of Biohaven BHVN.N fall 13.97% to $9.30 premarket
** Co said on Wednesday its experimental depression drug did not meet the main goal of a mid-stage trial
** Co is studying the drug BHV-7000 for the treatment of major depressive disorder
** Study miss is disappointing, brokerage William Blair says, but adds, as with many studies in MDD, we were cautious heading into this study, given difficulties in clinical trial execution and placebo creep in trials over recent years
** Up to last close, stock down 71% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Recent news on Biohaven
See all newsActing US FDA chief meets with rare disease groups to mend fences (updated)
Acting US FDA chief meets with rare disease groups to mend fences
Brief: Biohaven Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7.2/7.3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile
Brief: Biohaven Files For Offering Of Up To $350 Million Common Shares - SEC Filing
Brief: Biohaven Ltd Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing